Despite progress in preclinical studies on NF-κB signaling related treatment strategies, there are still many challenges in clinical trials that limit the widespread use and efficacy of these therapies in the clinical treatment of osteosarcoma. This evidence concerns the gene NFKB1 and osteosarcoma.